



(12) Translation of
European patent specification

(11) NO/EP 4219508 B1

NORWAY

(19) NO
(51) Int Cl.
C07D 498/14 (2006.01)
A61K 31/5383 (2006.01)
A61P 31/16 (2006.01)

Norwegian Industrial Property Office


(45)	Translation Published	2024.09.16
(80)	Date of The European Patent Office Publication of the Granted Patent	2024.06.05
(86)	European Application Nr.	23150186.7
(86)	European Filing Date	2016.04.27
(87)	The European Application's Publication Date	2023.08.02
(30)	Priority	2015.04.28, JP, 2015090909 2015.12.03, JP, 2015236844
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
(62)	Divided application	EP3290424, 2016.04.27
(73)	Proprietor	Shionogi & Co., Ltd, 1-8, Doshomachi 3-chome Chuo-ku, Osaka-shi, Osaka 541- 0045, Japan
(72)	Inventor	KAWAI, Makoto, Toyonaka-shi, 561-0825, Japan TOMITA, Kenji, Osaka-shi, 541-0045, Japan AKIYAMA, Toshiyuki, Toyonaka-shi, 561-0825, Japan OKANO, Azusa, Toyonaka-shi, 561-0825, Japan MIYAGAWA, Masayoshi, Toyonaka-shi, 561-0825, Japan
(74)	Agent or Attorney	ZACCO NORWAY AS, Postboks 488, 0213 OSLO, Norge

(54)	Title	SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVE AND PRODRUG THEREOF
(56)	References Cited:	WO-A1-2010/147068 WO-A1-2017/104691 WO-A1-2012/039414

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

- 1.** En forbindelse representert av den følgende formelen:




eller dets farmasøytisk akseptable salt,

for anvendelse ved behandling eller forebygging av en influensavirus-infeksjon.


15

- 2.** Forbindelsen for anvendelse i henhold til krav 1, hvor forbindelsen er representert av formelen:



20

- 3.** Forbindelsen for anvendelse i henhold til krav 1, hvor forbindelsen er representert av formelen:



- 4.** Forbindelsen eller dets farmasøytisk akseptable salt for anvendelse i henhold
5 til krav 1, hvor anvendelsen ved behandling eller forebygging av en
influensavirusinfeksjon er hos et menneske.
- 5.** Forbindelsen for anvendelse i henhold til krav 2 eller 3, hvor anvendelsen
ved behandling eller forebygging av en influensavirusinfeksjon er hos et
10 menneske.